Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)
8.10
-0.14 (-1.70%)
Nov 13, 2026, 3:00 PM CST
Tibet Weixinkang Medicine Revenue
Tibet Weixinkang Medicine had revenue of 232.33M CNY in the quarter ending September 30, 2026, a decrease of -15.90%. This brings the company's total for the last twelve months to 1.09B, down -6.71% year-over-year. In the year 2025, Tibet Weixinkang Medicine had annual revenue of 1.14B, down -12.65%. That makes Tibet Weixinkang Medicine the 18,963rd largest company in the world by revenue and 3,477th in China.
Revenue (ttm)
1.09B
Revenue Growth
-6.71%
P/S Ratio
3.21
Revenue / Employee
n/a
Employees
763
Market Cap
3.50B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.14B | -164.48M | -12.65% |
| Dec 31, 2024 | 1.30B | -22.41M | -1.69% |
| Dec 31, 2023 | 1.32B | -75.89M | -5.43% |
| Dec 31, 2022 | 1.40B | 364.92M | 35.31% |
| Dec 31, 2021 | 1.03B | 317.96M | 44.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Lianhuan Pharmaceutical | 2.96B |
| Jinhe Biotechnology CO., LTD. | 2.94B |
| Zhejiang Starry Pharmaceutical | 2.61B |
| Henan Taloph Pharmaceutical Stock Co.,Ltd | 1.70B |
| Qianjiang Yongan Pharmaceutical | 1.15B |
| Shandong Wohua Pharmaceutical | 781.18M |
| Newland Pharmaceutical | 733.72M |
| Shanghai Xiao Fang Pharmaceutical | 553.96M |